SCHEMBL27138757

SCHEMBL27138757

O=Cc1ccc2nc(N3CCOCC3)ccc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH3A1 P30838 1/20 0.51
▸ ALDH1A3 P47895 1/20 0.51
▸ MCHR1 Q99705 2/20 0.46
▸ GAA P10253 4/20 0.46
▸ NPC1 O15118 2/20 0.45
▸ RAB9A P51151 2/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ ALDH1A1 P00352 5/20 0.45
▸ HPGD P15428 4/20 0.45
▸ KDM4E B2RXH2 3/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ RECQL P46063 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ PIK3CD O00329 1/20 0.43
▸ PIK3CA P42336 1/20 0.43
▸ PIK3CB P42338 1/20 0.43
▸ PIK3CG P48736 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27108980 0.83 HTR3A (0.63) MCHR1KMT2AALDH1A1KDM4ECYP1A2
SCHEMBL27152269 0.83 ALDH3A1 (0.37) ALDH3A1ALDH1A3MCHR1NPC1RAB9A
SCHEMBL27144095 0.82 ALDH3A1 (0.39) ALDH3A1ALDH1A3MCHR1GAANPC1
SCHEMBL27145061 0.82 HTR3A (0.45) NPC1RAB9AALDH1A1KDM4ECYP1A2
SCHEMBL27139973 0.81 PDE10A (0.46) ALDH3A1ALDH1A3ALDH1A1CYP1A2CYP3A4
SCHEMBL27109006 0.81 HRH3 (0.44) ALDH1A1CYP1A2CYP3A4HTR3AHRH4
SCHEMBL31316122 0.81 HRH3 (0.41) NPC1RAB9AALDH1A1CYP1A2CYP3A4
SCHEMBL4196683 0.81 ALDH3A1 (0.49) ALDH3A1ALDH1A3GAANPC1RAB9A
SCHEMBL27138785 0.80 HCRTR1 (0.37) ALDH3A1ALDH1A3ALDH1A1CYP1A2CYP3A4
SCHEMBL27139164 0.80 HTR3A (0.37) ALDH3A1ALDH1A3MCHR1NPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4547658-A1 WEE1 DEGRADING COMPOUNDS AND USES THEREOF Bristol-Myers Squibb Company (US) 2025-05-07 — — EP disclosed
CN-119325469-A WEE1 degrading compounds and uses thereof 百时美施贵宝公司 2025-01-17 — — CN disclosed
US-20240067632-A1 WEE1 Degrading Compounds and Uses Thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2024-02-29 — — US disclosed
WO-2024006881-A1 WEE1 DEGRADING COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2024-01-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240067632-A1 WEE1 Degrading Compounds and Uses Thereof WEE1, WEE2, PPME1 ALDH3A1 3191/4885ALDH1A3 2975/4885MCHR1 4451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback